Clinic, Diagnostic Imaging and Radiopharmaceuticals

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Imaging Technology

DECEMBER 6, 2023

and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.

Diagnostic

Diagnostic Diagnostic Imaging Clinic Radiopharmaceuticals

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. Our ongoing Phase 1/2 clinical trial ( NCT05413850 ) is evaluating 177Lu-rhPSMA-10.1

Radiopharmaceuticals

Radiopharmaceuticals Radiosensitivity Medical Diagnostic

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic

Clinic Nuclear Medicine Radiopharmaceuticals Radiation

Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.

Nuclear Medicine

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging

Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.

Nuclear Medicine

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

JULY 28, 2023

The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. Chief Executive Officer of the Company. “We

Clinic

Clinic Diagnostic Radiopharmaceuticals Radiation

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical

Medical Radiopharmaceuticals Pharmaceutical Radiation

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Health Science

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine

Nuclear Medicine Radiopharmaceuticals Radiation Health Science

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. In clinical trials , the safety of POSLUMA was evaluated in 747 patients with initial or recurrent prostate cancer.

Diagnostic

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging

Visit TTG Imaging Solutions at ICE 2022

TTG Imaging Solutions

FEBRUARY 17, 2022

Be sure to visit us at booth #304 Monday, February 21 and Tuesday, February 22 to discover solutions for equipment, nationwide service, parts, and clinical support. We aim to maximize customer satisfaction through a relentless pursuit of quality, a broad portfolio of services, and commitment to continuous improvement.

Nuclear Medicine

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.

Diagnostic

Diagnostic Radiopharmaceuticals Imaging Radiation

TTG Imaging Solutions Acquires Digirad Health from Star Equity Holdings

TTG Imaging Solutions

MAY 5, 2023

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.

Imaging

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine

GE HealthCare Introduces Groundbreaking Developments in Precision Care at SNMMI24

Imaging Technology

JUNE 20, 2024

More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging. Additionally, with technology advancements and software upgrades, the lifespan of equipment can be extended and enhanced to help improve clinical outcomes.

Healthcare

Healthcare Healthcare Nuclear Medicine Computed Tomography

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Blue Earth Diagnostics received U.S.

Diagnose

Diagnose Diagnostic Disease Radiation

TTG Imaging Solutions, LLC Announces Executive Leadership Changes

TTG Imaging Solutions

NOVEMBER 1, 2021

The organization brought a robust customer base in the mid-west along with a strong group of field service engineers The following executive leadership changes are effective November 1, 2021: Jack Tomayko, Ph.D., Remaining in their current roles are John Nalley, EVP of Equipment Service Operations, and Hunter Forestier, VP of Sales and Marketing.

Nuclear Medicine

Nuclear Medicine Imaging Radiopharmaceuticals Medical Imaging

Diagnostic Imaging Brief

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

The rise of theranostics: Part 3 -- What is a theranostics center?

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations

Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

The rise of theranostics: Part 1 -- Gaining momentum

The rise of theranostics: Part 1 -- Gaining momentum

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Visit TTG Imaging Solutions at ICE 2022

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

TTG Imaging Solutions Acquires Digirad Health from Star Equity Holdings

GE HealthCare Introduces Groundbreaking Developments in Precision Care at SNMMI24

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

TTG Imaging Solutions, LLC Announces Executive Leadership Changes

Stay Connected